Brief: Aditxt Inc - Adimune Plans FDA Submission For Trials In Early 2026
25/08/2025 14:18
Aug 25 (Reuters) - Aditxt Inc ADTX.O: ADITXT INC - ADIMUNE PLANS FDA SUBMISSION FOR TRIALS IN EARLY 2026 Source text: ID:nBw9w7WG2a Further company coverage: ADTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aditxt
See all newsBrief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
Brief: Aditxt Appoints Jeffrey M. Busch As Interim CEO; Founder And Former CEO Of $1B NYSE Enterprise Which Delivered ~8.5% Dividends To Shareholders
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM